<DOC>
	<DOCNO>NCT02493738</DOCNO>
	<brief_summary>Study Objectives : - To evaluate pharmacokinetics ( PK ) orally administer Lozanoc fast fed condition healthy male subject - To compare pharmacokinetics ( PK ) orally administer Lozanoc Sporanox fed condition healthy male subject - To evaluate safety tolerability single oral dose Lozanoc Sporanox Korean healthy male subject</brief_summary>
	<brief_title>A Clinical Study Evaluate Pharmacokinetics Lozanoc Sporanox Korean Healthy Male Volunteers</brief_title>
	<detailed_description>Phase I Study divide 3 part write bellow . Part I. Lozanoc 50mg single dose feed condition v Part 2 . Lozanoc 50mg single dose fast condition v Part 3 . Sporanox 100mg single dose feed condition</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Histoplasmosis</mesh_term>
	<mesh_term>Dermatomycoses</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>1 . Korean male volunteer age 19 50 year old ( inclusive ) 2 . Subject able give sign informed consent 3 . Body mass index ( BMI ) range 19 28 kg/m2 weight least 50kg 4 . Subject consider Prestudy physical examination clinically significant abnormality No clinically significant medical history Vital sign within reference range , outside range , deem clinically significant opinion Investigator 90 mmHg ≤ systolic blood pressure ( sit position ) ≤ 140mmHg 50 mmHg ≤ diastolic blood pressure ( sit position ) ≤ 90 mmHg Prestudy clinical laboratory finding within reference range , outside range , deem clinically significant opinion Investigator No clinically significant abnormality 12lead ECG result 5 . Agree continue use least two accepted method birth control donate sperm least 1 day first dose , course study period 90days follow last dosing . Acceptable method birth control : female ( sexual partner ) hormonal contraceptive ; intrauterine device ; surgical sterility least 6 month prior screen ( Ex . hysterectomy , bilateral oophorectomy , and/or tubal ligation ) ; use diaphragm ; use condom ; spermicide Subjects exclude meet follow criterion : 1 . History allergy sensitivity drug , include prior serious adverse reaction antifungal agent ( ) 2 . History congestive heart failure Patients ventricular dysfunction congestive heart failure 3 . Undergone surgery medical condition , judgment Investigator , may affect absorption , distribution , metabolism elimination drug product 4 . Participated previous clinical trial within 90 day prior screen visit 5 . Donated blood significant loss blood within 60 day prior screen visit 6 . Special diet substantial change eat habit within 30 day prior screen visit 7 . Use prescription medication within 14 day screen visit 8 . Use OTC medication within 7 day screen visit 9 . History smoking within 3 month prior screen visit 10 . Have recent history ( within 2 year prior screen visit ) alcohol drug abuse positive screen drug abuse screen 11 . Positive blood screen HIV hepatitis B C syphilis 12 . Clinically important abnormal hepatic function test ( AST , ALT great 2 fold reference upper limit ( ULN ) , total bilirubin great 1.5 x ULN ) 13 . Not suitable participate study opinion Investigator include exist physical mental condition prevents compliance protocol</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>